Inzy stock forecast.

Dec 2, 2023 · The consensus price target of analysts on Wall Street is $21.00, which implies an increase of 81.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $40.00 respectively. As a result, INZY is trading at a discount of -938.96% off the target high and -289.61% off the low.

Inzy stock forecast. Things To Know About Inzy stock forecast.

Their INZY share price targets range from $6.00 to $23.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 289.6% from the stock's current price. View analysts price targets for INZY or view top-rated stocks among Wall Street analysts.Incyte has risen higher in 16 of those 30 years over the subsequent 52-week period, corresponding to a historical accuracy of 53.33%. Is Incyte Stock Undervalued? The current Incyte [ INCY] share price is $53.39. The Score for INCY is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.Analyst Forecast According to 4 analysts, the average rating for INZY stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 306.50% from the latest price.Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...

Find the latest Kintara Therapeutics, Inc. (KTRA) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Fangdd Network Group Ltd. (DUO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Troika Media Group, Inc. (TRKA) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Incyte Corporation (INCY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceINZY Stock 12 Months Forecast. $16.00. (315.58% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Inozyme Pharma in the last 3 months. The average price target is $16.00 with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 315.58% change from the last price of $3.85.Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Find the latest Alzamend Neuro, Inc. (ALZN) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Plus Therapeutics, Inc. (PSTV) stock quote, history, news and other vital information to help you with your stock trading and investing.

Stock Price Forecast. The 15 analysts offering 12-month price forecasts for Paycom Software Inc have a median target of 190.00, with a high estimate of 270.00 and a low estimate of 140.00. The ...

Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $12.95B. -12.7%. Market Cap / Employee. The market cap of a ...You can view all of the due diligence checks on INZY's stock page. How is INZY stock valued? Investors. use many financial metrics, analyses, models, and charts to gauge INZY's intrinsic value.Using relative valuations . measures:INZY; may be undervalued based on its P/B ratio of 1.42x, relative to Biotechnology industry P/B ratio of . 5.35xNasdaq Futures -44.75(-0.28%) Russell 2000 Futures 1,798.80 -12.20(-0.67%) Crude Oil 74.30 -1.24(-1.64%) Gold 2,013.20 +10.20(+0.51%) Inozyme Pharma, Inc. (INZY) NasdaqGS - NasdaqGS Real Time...Find the latest Phathom Pharmaceuticals, Inc. (PHAT) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Inozyme Pharma Inc have a median target of 16.00, with a high estimate of 40.00 and a low estimate of 15.00. The median ...

Based on 12 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $82.64 with a high forecast of $93.00 and a low forecast of $63.00. The average price target represents a 53.24% change from the last price of $53.93. Highest Price Target $93.00. Average Price Target $82.64.ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Symbol Lookup from Yahoo Finance. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Oct 13, 2023 · Incyte stock price predictions for 2023, 2024, 2025, 2026, 2027 using artificial intelligence. How much will Incyte cost in 2021-2025? Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Incyte has risen higher in 16 of those 30 years over the subsequent 52-week period, corresponding to a historical accuracy of 53.33%. Is Incyte Stock Undervalued? The current Incyte [ INCY] share price is $53.39. The Score for INCY is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.Find the latest Oncolytics Biotech Inc. (ONCY) stock quote, history, news and other vital information to help you with your stock trading and investing.

See Inozyme Pharma, Inc. (INZY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Sep 20, 2023 · Inozyme Pharma, Inc. (INZY) share price prediction for 2023, 2024, 2025, 2026 and 2027. INZY one year forecast. Inozyme Pharma stock monthly and weekly forecasts. In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.Find the latest Gaotu Techedu Inc. (GOTU) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest SciSparc Ltd. (SPRC) stock quote, history, news and other vital information to help you with your stock trading and investing.According to the issued ratings of 19 analysts in the last year, the consensus rating for Incyte stock is Hold based on the current 1 sell rating, 10 hold ratings and 8 buy ratings for INCY. The average twelve-month price prediction for Incyte is $79.94 with a high price target of $100.00 and a low price target of $61.00.President exercised options and sold US$65k worth of stock Jun 26. Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application …

Inozyme Pharma (INZY) Stock Forecast and Price Target 2023 S&P 500 4,559.34 DOW 35,390.15 QQQ 389.51 12 crew members are missing, 1 dead after a …

Find the latest MEI Pharma, Inc. (MEIP) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest Inozyme Pharma, Inc. (INZY) stock quote, history, news and other vital information to help you with your stock trading and investing.Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. INZY's 67 means that it ranks higher than 67% of stocks. Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good ...These Healthcare stocks are trading lower: -NanoViricides Inc ( NNVC) stock is trading at $1.35, a loss of $0.28, or 17.18%, on high volume. Nanoviricides Inc gets a Sentiment Score of Very Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.25. -180 Life Sciences Corp ( …Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Stockinvest.us Pricing Options. Stockinvest.us has a single pricing tier and costs 19.90/month or $199/year. There is also a five-day free trial for new users to try out the software. When you first sign up for the free trial, Stockinvest.us offers 20% off a plan for up to 24 hours. Try StockInvest.us for Free!Nov 14, 2023 · Inozyme Pharma Stock Forecast and Price Target. The average price target for Inozyme Pharma's stock set by recognized analysts recently is $23.00, which would result in a potential upside of approximately 701.39% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $5.00. 16 analysts have issued twelve-month price objectives for Alibaba Group's shares. Their BABA share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $129.20 in the next year. This suggests a possible upside of 74.6% from the stock's current price.Incyte Corp (INCY) $53.74 0.34 (0.64%) 13:00 EST INCY Stock Quote Delayed 30 Minutes.According to our current INZY stock forecast, the value of Inozyme Pharma shares will rise by 7.27% and reach $ 3.50 per share by November 24, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear). BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics …Incyte stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Incyte analysts is $ 76.35. Today 200 Day Moving Average is the resistance level (65.46 $). 50 Day Moving Average is the resistance level (56.93 $).Follow. BOSTON, July 23, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of ...

Get the latest Inozyme Pharma Inc (INZY) stock quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. See the company's financial results, market news, and earnings per share for the fiscal Q2 2023 ended 6/30/23. Find the latest MAIA Biotechnology, Inc. (MAIA) stock quote, history, news and other vital information to help you with your stock trading and investing.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comInstagram:https://instagram. jfk fifty cent piece valuewhere to buy stocks in canadamarketbeat comflot etf Find the latest Inozyme Pharma, Inc. INZY analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. …Nov 24, 2023 · The Incyte Corporation stock price gained 0.637% on the last trading day (Friday, 24th Nov 2023), rising from $53.40 to $53.74. During the last trading day the stock fluctuated 1.08% from a day low at $53.21 to a day high of $53.78. The price has risen in 7 of the last 10 days and is up by 2.32% over the past 2 weeks. ogeaxwhat is a stock price target Inozyme Pharma Inc. 3.23. Delayed Data. As of Nov 16. +0.03 / +0.94%. Today’s Change. 0.99. Today ||| 52-Week Range. 7.33. The Incyte Corporation stock price gained 0.637% on the last trading day (Friday, 24th Nov 2023), rising from $53.40 to $53.74. During the last trading day the stock fluctuated 1.08% from a day low at $53.21 to a day high of $53.78. The price has risen in 7 of the last 10 days and is up by 2.32% over the past 2 weeks. collectibles insurance agency Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).The stock market is poised to "zig-zag" towards record highs in December, with the S&P 500 rising 5% to 4,800, according to a Monday note from Fundstrat's Tom …